Order Article Reprints

Schmidt R, Rueger C, Xu H, He Y, Yilmaz EY, Heidemann L, Sulejmani O, Liu Y, Noack L, Hesse F, et al. Comparing the Prognostic Value of Quantitative Response Assessment Tools and LIRADS Treatment Response Algorithm in Patients with Hepatocellular Carcinoma Following Interstitial High-Dose-Rate Brachytherapy and Conventional Transarterial Chemoembolization. Cancers. 2025; 17(8):1275. https://doi.org/10.3390/cancers17081275

Schmidt, Robin, Christopher Rueger, Han Xu, Yubei He, Emine Yaren Yilmaz, Luisa Heidemann, Ornela Sulejmani, Yu Liu, Lasse Noack, Friederike Hesse, and et al. 2025. "Comparing the Prognostic Value of Quantitative Response Assessment Tools and LIRADS Treatment Response Algorithm in Patients with Hepatocellular Carcinoma Following Interstitial High-Dose-Rate Brachytherapy and Conventional Transarterial Chemoembolization" Cancers 17, no. 8: 1275. https://doi.org/10.3390/cancers17081275

Schmidt, R., Rueger, C., Xu, H., He, Y., Yilmaz, E. Y., Heidemann, L., Sulejmani, O., Liu, Y., Noack, L., Hesse, F., Ruppel, R., Abosabie, S. A., Hamm, C. A., Penzkofer, T., Gebauer, B., & Savic, L. J. (2025). Comparing the Prognostic Value of Quantitative Response Assessment Tools and LIRADS Treatment Response Algorithm in Patients with Hepatocellular Carcinoma Following Interstitial High-Dose-Rate Brachytherapy and Conventional Transarterial Chemoembolization. Cancers, 17(8), 1275. https://doi.org/10.3390/cancers17081275